当前位置: 首页 > 期刊 > 《中国医学创新》 > 2017年第19期
编号:13112904
瑞舒伐他汀钙治疗老年冠心病合并高脂血症的疗效分析(1)
http://www.100md.com 2017年7月5日 《中国医学创新》 2017年第19期
     【摘要】 目的:研究瑞舒伐他汀鈣治疗老年冠心病合并高脂血症的效果。方法:选取本院2015年5月-2016年12月收治的老年冠心病合并高脂血症患者150例为研究对象,按照随机数字表法将其分为对照组和观察1组、观察2组,每组各50例。对照组采用阿托伐他汀钙治疗,观察1组采用10 mg/d瑞舒伐他汀钙治疗,观察2组采用20 mg/d瑞舒伐他汀钙治疗。对比两组治疗总有效率、血脂指标、不良反应发生率等。结果:观察2组治疗总有效率(100%)高于观察1组(90.0%)和对照组(84.0%),差异均有统计学意义(P<0.05)。治疗4周后,三组血脂指标水平均有明显改善(P<0.05),而观察2组改善幅度最大(P<0.05)。三组治疗期间不良反应发生率和不良心脏事件发生率比较,差异均无统计学意义(P>0.05)。结论:大剂量的瑞舒伐他汀钙(20 mg/d)治疗老年冠心病合并高脂血症效果确切,且安全性高,有助于促进患者血脂水平的降低,控制病情进展,值得在临床上推广应用。

    【关键词】 瑞舒伐他汀钙; 阿托伐他汀; 老年冠心病; 高脂血症; 不良反应; 血脂

    Efficacy of Rosuvastatin Calcium Tablets in the Treatment of Elderly Patients with Coronary Heart Disease Complicated with Hyperlipidemia/MIAO Jin-long.//Medical Innovation of China,2017,14(19):041-045

    【Abstract】 Objective:To study Rosuvastatin Calcium Tablets in the treatment of senile coronary heart disease(CHD) combined with hyperlipidemia.Method:A total of 150 elderly patients with coronary heart disease complicated with hyperlipidemia treated in our hospital from May 2015 to December 2016 were selected as the study subjects and divided into the control group,the observation 1 group and the observation 2 group according to random number table method,50 cases in each group.The control group was treated with Atorvastatin Calcium Tablets,the observation 1 group was treated with Rosuvastatin Calcium Tablets,10 mg/d,the observe 2 group were treated by Rosuvastatin Calcium Tablets,20 mg/d.Total effective rate,blood fat indexes,incidence of adverse reactions of three groups were compared.Result:The total effective rate of the observe 2 group was 100% higher than that of the observation 1 group 90.0% and the control group 84.0%,the differences were statistically significant(P<0.05).After 4 weeks of treatment,the levels of TC,TG,LDL-C and HDL-C of three groups were significantly improved(P<0.05),the improve of the observation 2 group was the most obvious(P<0.05).There was no significant difference in the incidence of adverse reactions and adverse cardiac events during the treatment of three groups(P>0.05).Conclusion:High dose of Rosuvastatin Calcium Tablets(20 mg/d) in treatment of elderly patients with coronary heart disease combined with hyperlipidemia has significant effect and high safety,it contributes to reduce the blood lipid levels of patients and control the progress of the disease,it is worthy of clinical application.

    【Key words】 Rosuvastatin Calcium Tablets; Atorvastatin Calcium Tablets; Coronary heart disease; Hyperlipidemia; Adverse reaction; Blood lipid, 百拇医药(缪金龙)
1 2 3下一页